|22 September 2011|
|With patent protection over some of the world’s most expensive drugs nearing their expiry date or in (some/many) cases having already expired, the race to create copies of these drugs to be sold at far cheaper prices is well and truly underway. |
In this Boardroom Radio interview, Wayne Condon and Dr Stuart Boyer discuss this ‘biosimilars’ development and how this will affect the Australian market.
|Click here for the full interview.|
|Brought to you in partnership with Boardroom Radio Australia|